Differentiated Strategies for the Therapy of Liver Metastases in Gastro-entero-pancreatic Neuroendocrine Neoplasia

被引:1
|
作者
Mogl, Martina T. [1 ]
Oellinger, Robert [1 ,2 ]
Jann, Henning [3 ]
Gebauer, Bernhard [4 ]
Fehrenbach, Uli [4 ]
Amthauer, Holger [5 ]
Wetz, Christoph [5 ]
Schmelzle, Moritz [1 ]
Raschzok, Nathanael [1 ]
Krenzien, Felix [1 ]
Goretzki, Peter E. [1 ]
Pratschke, Johann [1 ]
Schoening, Wenzel [1 ]
机构
[1] Charite Univ Med Berlin, Chirurg Klin, Campus Charite Mitte, Campus Virchow Klinikum, Charitepl 1, D-10117 Berlin, Germany
[2] Charite Univ Med Berlin, Europa Metastasenzentrum Charite, Berlin, Germany
[3] Charite Univ Med Berlin, Med Klin Hepatol & Gastroenterol, Berlin, Germany
[4] Charite Univ Med Berlin, Klin Radiol, Berlin, Germany
[5] Charite Univ Med Berlin, Klin Nukl Med, Berlin, Germany
来源
ZENTRALBLATT FUR CHIRURGIE | 2022年 / 147卷 / 03期
关键词
liver metastasis; neuroendocrine neoplasia; neuroendocrine tumor; locally ablative therapy; Nuclear medicine; ENETS CONSENSUS GUIDELINES; PORTAL-VEIN LIGATION; HEPATIC METASTASES; TUMORS; RESECTION; TRANSPLANTATION; ABLATION; SURGERY; BRACHYTHERAPY; EMBOLIZATION;
D O I
10.1055/a-1830-8442
中图分类号
R61 [外科手术学];
学科分类号
摘要
Neuroendocrine neoplasias comprise a heterogenous group of malignant tumours, mostly arising from the gastro-enteropancreatic system (GEP). Most of these tumours develop from the small intestine and pancreas and the liver is the predominant site for distant metastases. Patients may be asymptomatic for a long time and liver metastases are frequently diagnosed by chance or during operations for bowel obstruction, for example, during emergency surgery. The only curative therapy consists in complete removal of primary and metastases. In case of metastatic disease, various treatment modalities need to be discussed in interdisciplinary tumour boards comprised of specialists from gastroenterology, (liver-) surgery, radiology, nuclear medicine, radiotherapy, pathology and endocrinology. By combining different therapies, even patients with progressive disease may reach long-term overall survival with good quality of life. The most important factors for decisions on therapy are individual factors like tumour grading, hormonal functionality, type of metastases and evolution of the disease. Adequate treatment of liver metastases comprises various surgical strategies as well as locally ablative radiological interventions and nuclear medical therapies, in complement to systemic treatments.
引用
收藏
页码:270 / 280
页数:11
相关论文
共 50 条
  • [31] Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumors or multiple endocrine neoplasia type 1
    Peracchi, M
    Conte, D
    Gebbia, C
    Penati, C
    Pizzinelli, S
    Arosio, M
    Corbetta, S
    Spada, A
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2003, 148 (01) : 39 - 43
  • [32] Aggressive gastro-entero-pancreatic neoplasms
    Coriat, Romain
    ANNALES D ENDOCRINOLOGIE, 2019, 80 (03) : 185 - 186
  • [33] Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: A SEER-based analysis
    Zheng, Mengzhen
    Li, Yan
    Li, Tong
    Zhang, Lianfeng
    Zhou, Lin
    CANCER MEDICINE, 2019, 8 (11): : 5128 - 5136
  • [34] Analysis of molecular pathways in sporadic neuroendocrine tumors of the gastro-entero-pancreatic system
    Arnold, Christian N.
    Sosnowski, Andrea
    Schmitt-Graeff, Annette
    Arnold, Rudolf
    Blum, Hubert E.
    INTERNATIONAL JOURNAL OF CANCER, 2007, 120 (10) : 2157 - 2164
  • [35] Palliative cytoreductive surgery versus other palliative treatments in patients with unresectable liver metastases from gastro-entero-pancreatic neuroendocrine tumours
    Gurusamy, Kurinchi Selvan
    Pamecha, Viniyendra
    Sharma, Dinesh
    Davidson, Brian R.
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (01):
  • [36] Insurance-based Disparities in Gastro-Entero-Pancreatic Neuroendocrine Tumor Patients
    Baechle, Jordan J.
    Smith, Paula Marincola
    Idrees, Kamran
    JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED, 2021, 32 (03) : 1199 - 1207
  • [37] Does biopsy reliably identify grade in gastro-entero-pancreatic neuroendocrine tumors?
    Grillo, F.
    Brisigotti, M. P.
    Albertelli, M.
    Rossi, C.
    Fiocca, R.
    Mastracci, L.
    VIRCHOWS ARCHIV, 2013, 463 (02) : 145 - 145
  • [38] Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma
    Akira Ooki
    Hiroki Osumi
    Koshiro Fukuda
    Kensei Yamaguchi
    Cancer and Metastasis Reviews, 2023, 42 : 1021 - 1054
  • [39] Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma
    Ooki, Akira
    Osumi, Hiroki
    Fukuda, Koshiro
    Yamaguchi, Kensei
    CANCER AND METASTASIS REVIEWS, 2023, 42 (03) : 1021 - 1054
  • [40] Dose Escalation of Octreotide Acetate for Management of Gastro-entero-pancreatic Neuroendocrine Tumors
    Chadha, Manpreet
    Chadha, Krishdeep
    Lombardo, Jeffery
    Mashtare, Terry
    Wilding, Gregory
    Gibbs, John
    Kuvshinoff, Boris
    Litwin, Alan
    Raczyk, Cheryl
    Javle, Milind
    Iyer, Renuka
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 : S103 - S103